Company profile
Entia Biosciences, Inc.
OTC: ERGO · Healthcare · Medical - Pharmaceuticals
#979 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
——FH —DQ 31GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, listing tenure · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$265.5k
Rev growth YoY (TTM)
-23.5%
Net income (FY)
-$1.4M
Employees
6
as of 2026-08-30
Market cap
$26.9k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$265.5k$265.5k2016
Net income-$1.4M-$1.4M2016
Operating income-$1.3M-$1.3M2016
Total assets$439.1k$439.1k2016
Liabilities$2.4M$2.4M2016
Equity-$2.0M-$2.0M2016
Revenue trend
FY2011 – FY2016 · USD
FY11
FY11
FY12
FY13
FY14
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Entia Biosciences, Inc.’s revenue?
Entia Biosciences, Inc. booked $265.5k in FY2016 revenue, contracting 23% year over year — slower than 73% of Healthcare companies we track, at a -525.8% net margin.
Peers · Healthcare
Hydrogen Hybrid Technologies, Inc.——Aion Therapeutic Inc.——Abattis Bioceuticals Corp.——CEL-SCI Corporation32DNutra Pharma Corp.30DNewCardio, Inc.——Neighbors
Washington →Key facts
CEOTimothy A. Timmins
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersSherwood, OR
ExchangeOTC: ERGO
Employees6
IPO date2008-01-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.